News | May 25, 2022
IPCA Laboratories posts Rs. 130.23 crores consolidated profit in Q4FY22
The company has posted net profit of Rs.884.08 crores for the Financial Year ended March 31, 2022.
The company has posted net profit of Rs.884.08 crores for the Financial Year ended March 31, 2022.
The vaccine was found to have 64% efficacy against symptomatic disease and 92% against severe Covid-19
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
Cipla has reported consolidated financial results for the period ended March 31, 2022
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
Digital PCR format allows for rapid turnaround time to facilitate fast and accurate post-transplant treatment decisions
The EBUS is designed to support the diagnosis and staging of various lung disorders
Formula attenuates 99% of 365 coronaviruses in computer models
Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
Subscribe To Our Newsletter & Stay Updated
